Events

­

Quark will present at TIDES: Oligonucleotide Therapeutics Discovery. Providence, RI, May 12-15, 2014.

April 12th, 2014|

Use of siRNA for Treatment of Inner Ear Diseases.

Quark Pharmaceuticals to Participate in IBC’s Oligonucleotide Therapeutics: From Concept to Implementation Conference

August 3rd, 2009|

Fremont, CA – August 3, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will participate in multiple roles at IBC’s Oligonucleotide Therapeutics: from Concept to Implementation Conference. The conference will take place August 3-5, 2009 in […]

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

May 11th, 2009|

Fremont, CA – May 11, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, “PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation,” at […]

Quark Pharmaceuticals Presents at American Society for Pharmacology and Experimental Therapeutics Annual Meeting

April 20th, 2009|

Fremont, CA – April 20, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will give a presentation on Tuesday, April 21 at this year’s American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting, which […]

Quark Pharmaceuticals Presents at Asia TIDES Conference

March 9th, 2009|

 Highlights First Systemic siRNA Administered in Humans and Quark’s Proprietary siRNA Structures

Fremont, CA – March 9, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development presented an overview of Quark’s novel pipeline of synthetic siRNA compounds […]

Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference

December 1st, 2008|

Presentation to Highlight Results of Ocular Neuroprotection Candidate 
Fremont, CA (December 1, 2008) –   Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its Chief Operating Officer, Dr. Rami Skaliter is scheduled to present results on the Company’s ocular neuroprotection candidate at the 20th Annual Piper Jaffray […]

Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008

September 17th, 2008|

Quark Pharmaceuticals Announces Poster Presentations at RNAI Europe 2008

Fremont, California, September 17, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced the presentation of posters at the 5th Annual RNAi Europe, taking place September 16-18, 2008 in Stockholm, Sweden. Three of Quark’s scientists, Igor Mett, […]

Quark to Present at JPMorgan 26th Annual Healthcare Conference

December 20th, 2007|

Preclinical Developments to be Highlighted: Delivery of siRNA to Bone Marrow and Proof of Concept Study Results –

Fremont, California, December 20, 2007  –  Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates, announced today that it is scheduled to present at the JPMorgan 26th Annual Healthcare Conference on […]

Quark to Present at CIBC and Acumen BioFin Rodman & Renshaw

October 9th, 2007|

Fremont, California, October 9, 2007 – Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it is scheduled to present on Tuesday, November 6, 2007 at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference and the CIBC World Markets 18th Annual Healthcare Conference. […]